Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr 29;184(5):318.
doi: 10.1007/s00431-025-06126-4.

Glanzmann thrombasthenia: a multi-center study of demographics, clinical spectrum, and treatment efficacy

Laila M Sherief  1 , Magdy El Ekiaby  2 , Mahmoud El-Hawy  3 , Eslam Elhawary  4 , Amira A Nazim  5 , Samar M Elbahy  6
Affiliations
Multicenter Study

Glanzmann thrombasthenia: a multi-center study of demographics, clinical spectrum, and treatment efficacy

Laila M Sherief et al. Eur J Pediatr. .

Abstract

Glanzmann thrombasthenia (GT) is a rare inherited bleeding disorder caused by quantitative or qualitative defects of platelet integrin GPIIb/IIIa (CD41 and CD61). This study intended to describe the demographics, clinical features, and treatment response of GT patients in several hematology centers in Egypt. A cross-sectional multi-center study involved 87 children (<18 years old) diagnosed with GT. Clinical data were recorded as bleeding manifestations, response to treatment modalities, and laboratory results. The study included eighty-seven children (61 females and 26 males) with a median age of 8 years. Sixty-one children (55.2%) were born to parents who were consanguineous. The median age at presentation was 3 years (birth-14 years). The most frequent initial presenting symptom was epistaxis (39.1%), followed by cutaneous bleeding (29.9%), gastrointestinal bleeding (23%), heavy menstrual bleeding (19.5%), bleeding per gum (10.3%), and post-circumcision bleeding (5.7%), while one patient initially presented with intracranial hemorrhage (1.1%). These also constituted common bleeding sites. Eighty children (92%) received treatment. Platelet transfusions were given to 65 patients, with a response rate of 73.8%, and recombinant factor VII concentrates were given to 71 patients, with a response rate of 90.1%. Type I GT represented most of our patients (79.3%), followed by type III (11.5%) and type II (9.2%). No significant correlation was found between CD41/CD61 expression and other parameters as the patient's age, bleeding frequency, and treatment response. There was no evident difference between the three forms of GT regarding clinical characteristics such as bleeding severity or response to treatment. What is known: • Glanzmann thrombasthenia is the most common inherited platelet function abnormality. • Treatment is based on general supportive measures, platelet transfusion and recombinant factor VIIa. What is new: • Glanzmann thrombasthenia is an underestimated disorder, with a significant delay in diagnosis. • Although it has three types, there is no significant variation in bleeding phenotype between them.

Keywords: Bleeding; Glanzmann thrombasthenia; Platelets; Recombinant factor VII.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This study was conducted in compliance with the 1964 Declaration of Helsinki and its subsequent amendments and received approval from the Research Ethics Committee at the Faculty of Medicine, Benha University (MoHP No: 0018122017/Certificate No: 1017). Consent to participate: Written informed consent was obtained from parents/guardians. Competing interests: The authors declare no competing interests.

References

    1. Botero JP, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W et al (2020) Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica 105(4):888–894. https://doi.org/10.3324/haematol.2018.214239 - DOI - PubMed - PMC
    1. Krause KA, Graham BC (2023) Glanzmann Thrombasthenia. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538270/
    1. Tarawah A, Owaidah T, Al-Mulla N, Khanani M, Elhazmi J, Albagshi M, Wali Y, Almohareb S, Almomen A (2019) Management of Glanzmann’s Thrombasthenia-Guidelines based on an expert panel consensus from gulf cooperation council countries. J Appl Hematol 10(1):1–9. https://doi.org/10.4103/joah.joah_68_18 - DOI
    1. Franchini M, Favaloro EJ, Lippi G (2010) Glanzmann thrombasthenia: an update. Clinica Chimica Acta 411(1–2):1–6. https://doi.org/10.1016/j.cca.2009.10.016 - DOI
    1. Nurden AT, Pillois X, Nurden P (2012) Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Rev Hematol 5(5):487–503. https://doi.org/10.1586/ehm.12.46 - DOI - PubMed

Publication types

LinkOut - more resources